8-K: Phreesia Reports Strong 2024 Growth, Eyes Profitability in 2025

Phreesia announced its fiscal year 2024 results, highlighting a 27% revenue increase and a strategic move to establish a subsidiary in India, while projecting a return to profitability in fiscal year 2025.

Summary

• Phreesia's total revenue for fiscal year 2024 reached $356.3 million, a 27% increase year-over-year.
• The company facilitated over 150 million patient visits in fiscal year 2024, representing more than one in ten patient visits across the U.S.
• The average number of healthcare services clients (AHSCs) grew by 26% to 3,601 in fiscal year 2024.
• Net loss for fiscal year 2024 was $136.9 million, an improvement from the $176.1 million loss in fiscal year 2023.
• Adjusted EBITDA for fiscal year 2024 was negative $35.4 million, compared to negative $92.5 million in the previous year.
• Phreesia is maintaining its revenue outlook for fiscal year 2025 at a range of $424 million to $434 million, projecting 19% to 22% year-over-year growth.
• The company updated its Adjusted EBITDA outlook for fiscal year 2025 to a range of $12 million to $20 million.
• Phreesia is establishing a wholly-owned subsidiary in India, Phreesia India Private Limited, to transition various outside services in-house.
• The company expects to commence operations through Phreesia India by the end of its first fiscal quarter, subject to regulatory approvals.
• Phreesia's global headcount is expected to reach approximately 2,400 after the transition to Phreesia India is complete.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, significant improvements in losses, and a clear path to profitability. However, there are still some concerns about the decrease in cash and cash equivalents and the slight decline in some per-AHSC metrics.

Positives

• Phreesia experienced strong revenue growth of 27% for the full fiscal year 2024.
• The company is showing significant improvement in reducing net losses and Adjusted EBITDA losses year-over-year.
• Phreesia is projecting a return to profitability in fiscal year 2025.
• The company is expanding its operations by establishing a subsidiary in India to improve efficiency.
• Phreesia's patient visit volume is substantial, indicating a strong market presence.
• The company is focused on improving operating leverage and efficiency.
• Phreesia's new medication adherence product, Post-Script Engagement, is gaining recognition.
• The company is committed to accessibility and security, as evidenced by product updates and PCI DSS Level 1 re-certification.
• Phreesia is recognized for its positive workplace culture.

Negatives

• Healthcare services revenue per AHSC decreased by 1% year-over-year for both the quarter and the full fiscal year.
• Total revenue per AHSC decreased by 2% year-over-year in the fourth quarter.
• The company experienced a decrease in cash and cash equivalents from $176.7 million to $87.5 million year-over-year.
• Phreesia is still operating at a net loss, although losses are decreasing.
• The company's payment processing gross margin decreased slightly in the fourth quarter.
• The inclusion of ConnectOnCall AHSCs negatively impacted total revenue per AHSC.

Risks

• There is a risk that Phreesia may not obtain the necessary licenses or approvals to commence operations in India on its expected timeline.
• There is a risk that current employees of the company's existing third-party service provider may not accept employment with Phreesia India.
• The company may not realize the intended benefits of transitioning outside services in-house through a subsidiary in India.
• There are risks associated with managing a global workforce remotely.
• The company faces risks associated with its limited operating history and compliance with local laws and regulations in India.
• The recent high inflationary environment and other general, market, political, economic and business conditions could impact the company.
• The company's ability to achieve its financial outlook is subject to various market and operational risks.
• There are risks associated with the company's ability to effectively manage growth and meet growth objectives.
• The company faces competition in the market.
• There are risks associated with the company's ability to develop and release new products and services.

Future Outlook

Phreesia is maintaining its revenue outlook for fiscal year 2025 at a range of $424 million to $434 million, implying year-over-year growth of 19% to 22%. The company updated its Adjusted EBITDA outlook for fiscal year 2025 to a range of $12 million to $20 million. Phreesia believes it will achieve its fiscal year 2026 Annualized Revenue Target of $500 million.

Management Comments

• Phreesia ended fiscal year 2024 with strong momentum going into fiscal 2025, said CEO and Co-Founder Chaim Indig.
• We are confident that our solutions and our team position us for continued growth and a return to profitability, said CEO and Co-Founder Chaim Indig.
• We remain focused on driving long-term value for all of our stakeholders, said CEO and Co-Founder Chaim Indig.

Industry Context

Phreesia operates in the healthcare technology sector, providing patient engagement and payment solutions. The company's focus on digital solutions aligns with the broader industry trend of increasing adoption of technology to improve patient experience and operational efficiency. The establishment of a subsidiary in India reflects a common strategy among tech companies to leverage global talent pools for cost-effective operations.

Comparison to Industry Standards

• Phreesia's revenue growth of 27% for fiscal year 2024 is strong compared to many established healthcare technology companies, but it is important to note that many of these companies are already profitable.
• The company's focus on Adjusted EBITDA improvement is a common metric used in the tech industry to demonstrate progress towards profitability, and Phreesia's improvement from negative $92.5 million to negative $35.4 million is significant.
• The company's patient visit volume of 150 million is substantial, indicating a strong market presence, but it is difficult to compare this directly to other companies without knowing their specific metrics.
• Phreesia's move to establish a subsidiary in India is a common practice among tech companies to reduce costs and access talent, similar to companies like Infosys and Tata Consultancy Services.
• The company's payment processing gross margin of 33% is within the range of other payment processing companies, but it is important to note that this is a competitive market.

Stakeholder Impact

• Shareholders will be impacted by the company's improved financial performance and path to profitability.
• Employees will be impacted by the expansion of the company's workforce through Phreesia India.
• Customers will benefit from the company's continued investment in its products and services.
• Suppliers may be impacted by the company's transition of outside services in-house.
• Creditors will be impacted by the company's improved financial stability.

Next Steps

• Phreesia will commence operations through Phreesia India by the end of its first fiscal quarter, subject to regulatory approvals.
• The company will continue to focus on improving efficiency and operating leverage.
• Phreesia will continue to develop and release new products and services.
• The company will hold a conference call on March 14, 2024, to review its fiscal year 2024 and fiscal fourth quarter financial results.

Key Dates

Keywords

Phreesia, healthcare technology, patient engagement, digital health, revenue growth, EBITDA, profitability, healthcare services, payment processing, network solutions, patient visits, AHSC, India subsidiary, vaccine management, medication adherence